Aktienanalyse zu Harvard Bioscience Inc (HBIO)HBIOHarvard Bioscience Inc

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Harvard Bioscience Inc is a good buy right now due to its recent revenue growth of 11% year-over-year, reaching $22.7 million in Q2 2026, and a current price of $8.60, which is still below the analyst target of $7.50. The company has also shown resilience with a 5-day change of +3.37% and a year-to-date change of +31.92%. However, the main risk is the negative net income, which was -2.9 million in Q2 2026, indicating ongoing profitability challenges.

3 analysts cover HBIO: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 2.00.